Quantitative NMR spectroscopy of biologically active substances and excipients

Bioanalytical Reviews

Volumn 2, Issue 1, 2010, Pages 1-22

  Beyer, Tanja ^a   Diehl, Bernd ^b   Holzgrabe, Ulrike ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Spectral Service   (Germany)

Author keywords

Active pharmaceutical ingredients; Amino acid; European pharmacopoeias; Heparin; Lipid; Quantitative NMR spectroscopy

Indexed keywords

ALANINE; AMINO ACID DERIVATIVE; AMYL NITRITE; BUSERELIN; CHOLESTEROL; COD LIVER OIL; EDETIC ACID; EXCIPIENT; FATTY ACID DERIVATIVE; GLUTAMINE; GLYCOSAMINOGLYCAN; GOSERELIN; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPARIN; HYDROCORTISONE SODIUM PHOSPHATE; LIPID; LOW MOLECULAR WEIGHT HEPARIN; MEDRONIC ACID; MENINGOCOCCUS VACCINE; ORGANIC COMPOUND; PHOSPHOLIPID; PNEUMOCOCCUS VACCINE; POLOXAMER; POLYSACCHARIDE; PROLINE; TERPENE DERIVATIVE; TOBRAMYCIN; UNINDEXED DRUG; UNSATURATED FATTY ACID; VEGETABLE OIL;

ACCURACY; AMINO ACID ANALYSIS; ANALYTIC METHOD; ANALYTICAL PARAMETERS; CALIBRATION; CAPILLARY ELECTROPHORESIS; CARBOHYDRATE ANALYSIS; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; DRUG IDENTIFICATION; DRUG PURITY; DRUG SCREENING; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERMETHOD COMPARISON; LIPID ANALYSIS; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RAMAN SPECTROMETRY; REVIEW; STANDARDIZATION; TEMPERATURE SENSITIVITY; ULTRAVIOLET SPECTROSCOPY;

EID: 77957923240     PISSN: 18672086     EISSN: 18672094     Source Type: Journal    
DOI: 10.1007/s12566-010-0016-8     Document Type: Review

References (121)

1. Quinn TJ (1997) Primary methods of measurements and primary standards. Metrologia 34: 61-65.
2. Malz F, Jancke H (2005) Validation of quantitative NMR. J Pharm Biomed Anal 38: 806-812.
3. Holzgrabe U, Deubner R, Schollmayer C, Waibel B (2005) Quantitative NMR spectroscopy-applications in drug analysis. J Pharm Biomed Anal 38: 806-812.
4. Diehl B (2008) NMR applications for polymer characterization. In: Holzgrabe U, Wawer I, Diehl B (eds) NMR spectroscopy in pharmaceutical analysis. Elsevier, Amsterdam, pp 157-180.
5. European Pharmacopoeia (2010) Peptide identification (2. 2. 64). Council of Europe, Strasbourg.
6. Jones C, Ravenscroft N (2008) NMR assay for Carbohydrate-based vaccines. In: Holzgrabe U, Wawer I, Diehl B (eds) NMR spectroscopy in pharmaceutical analysis. Elsevier, Amsterdam, pp 341-368.
7. 1H NMR spectroscopy: constrained total-line-shape fitting. Anal Chim Acta 542: 178-185.
8. 1H NMR spectroscopy. J Pharm Biomed Anal 52: 51-58.
9. Pauli GF, Kuczkowiak U, Nahrstedt A (1999) Solvent effects in the structure dereplication of caffeoyl quinic acids. Magn Reson Chem 37: 827-836.
10. 1H chemical shifts. Magn Reson Chem 44: 491-509.
11. Jones IC, Sharman GJ, Pidgeon J (2005) Spectral assignments and reference data. Magn Reson Chem 43: 497-509.
12. Laszlo P (1967) Solvent effects and nuclear magnetic resonance. In: Emsley JW, Feeney F, Sutcliffe LH (eds) Progress in nuclear magnetic resonance spectroscopy, vol 3. Pergamon, Oxford, pp 231-402.
13. Buckingham AD, Schaefer T, Schneider WG (1960) Solvent effects in nuclear magnetic resonance spectra. J Phys Chem 32: 1227-1234.
14. Schneider WG (1962) Directed solute-solvent interactions in benzene solutions. J Phys Chem 66: 2653-2657.
15. 13C NMR. Prog NMR Spectrosc 29: 129-168.
16. Buckingham DA, Clark CR, Nangia A (1990) The acidity of norfloxacin. Aust J Chem 43: 301-309.
17. 13C NMR spectral data of fifteen gyrase inhibitors and some metabolites. Magn Reson Chem 32: 192-197.
18. 1H NMR pH indicator compound set for deuterium oxide solutions. Anal Chim Acta 648: 105-112.
19. Holzgrabe U, Nap CJ, Beyer T, Almeling S (2010) Alternatives to amino-acid-analysis for the purity control of pharmaceutical grade l-alanine. J Sep Sci. doi: 10. 1002/jssc. 201000141.
20. 1H nuclear magnetic resonance study. J Chem Soc D9: 524-525.
21. 1H-NMR studies: a caveat in the investigations of molecular recognition and structure elucidation. Tetrahedron 54: 15489-15498.
22. Michaleas S, Antoniadou-Vyza E (2006) A new approach to quantitative NMR: fluoroquinolones analysis by evaluating the chemical shift displacements. J Pharm Biomed Anal 42: 405-410.
23. Casy AF (1993) Chiral disrimination by NMR spectroscopy. TrAC 12: 185-189.
24. 1H NMR spectroscopy. Magn Reson Chem 26: 765-774.
25. Thunhorst M, Holzgrabe U (1998) Utilizing NMR spectroscopy for assessing drug enantiomeric composition. Magn Reson Chem 36: 211-216.
26. 1H NMR spectral simplification with achiral and chiral lanthanide shift reagents. Clenbuterol. Method for direct optical purity determination. Spectrosc Lett 22: 511-532.
27. Gottlieb HE, Kotlyar V, Nudelman A (1997) NMR chemical shifts of common laboratory solvents as trace impurities. J Org Chem 62: 7512-7515.
28. 1H nuclear magnetic resonance spectroscopy. J Pharm Biomed Anal 48: 13-19.
29. Claridge TDW (1999) High-resolution NMR techniques in organic chemistry. Pergamon, Amsterdam.
30. Holzgrabe U (2010) Quantitative NMR spectroscopy in pharmaceutical applications. Prog NMR Spectrosc 57(2): 229-240.
31. Beyer T, Holgrabe U (2008) Investigation of multi-component drugs by NMR spectroscopy. In: Holzgrabe U, Wawer I, Diehl B (eds) NMR spectroscopy in pharmaceutical analysis. Elsevier, Amsterdam, pp 141-155.
32. 1H NMR: development and potential of a method for natural products analysis. J Nat Prod 68: 133-149.
33. Pauli GF, Jaki BU, Lankin DC (2007) A routine experimental protocol for qHNMR illustrated with taxol. J Nat Prod 70: 589-595.
34. Malz F (2008) Quantitative NMR in the solution state NMR. In: Holzgrabe U, Wawer I, Diehl B (eds) NMR spectroscopy in pharmaceutical analysis. Elsevier, Amsterdam, pp 43-62.
35. 1H-NMR studies of drugs with chiral solvating agent: the direct enantiomeric purity determination of the chiral anesthetic, prilocaine. Enantiomers 5: 303-312.
36. 1H NMR method for the routine spectroscopic determination of enantiomeric purity of active pharmaceutical ingredients fenfluramine, sertraline, and paroxetine. Magn Reson Chem 43: 910-917.
37. Wells RJ, Hook JM, Al-Deen TS, Hibbert DB (2002) Quantitative nuclear magnetic resonance (QNMR) spectroscopy for assessing the purity of technical grade agrochemicals: 2, 4-Dichlorophenoxyacetic acid (2, 4-D) and sodium 2, 2-dichloropropionate (dalapon sodium). J Agric food chem 50: 3366-3374.
38. Al-Deen TS, Hibbert DB, Hook JM, Wells RJ (2004) An uncertainty budget for the determination of the purity of glyphosate by quantitative nuclear magnetic resonance (QNMR) spectroscopy. Accred Qual Assur 9: 55-63.
39. 1H NMR spectroscopy. J Pharm Biomed Anal 52: 645-651.
40. Rabenstein DL, Keire DA (1991) Quantitative chemical analysis by NMR. In: Popov AI, Hallenga K (eds) Modern NMR techniques and their application in chemistry. Marcel Dekker, New York, pp 323-369.
41. Freeman R (1997) Handbook of nuclear magnetic resonance. Addison Wesley Longman, Edinburgh.
42. 1H nuclear magnetic resonance spectroscopy analysis for simultaneous determination of levodopa, carbidopa and methyldopa in human serum and pharmaceutical formulations. Anal Chim Acta 506: 97-104.
43. 1H-NMR spectroscopy. J Pharm Biomed Anal 21: 467-472.
44. Bilia AR, Bergonzi MC, Lazari D, Vincieri FF (2002) Characterization of commercial kava-kava herbal drug and herbal drug preparations by means of nuclear magnetic resonance spectroscopy. J Agric Food Chem 50: 5016-5025.
45. Wells RJ, Cheung J, Hook JM (2004) Dimethylsulfone as a universal standard for analysis of organics by Q NMR. Accred Qual Assur 9: 450-456.
46. Kromidas S (2005) Validierung in der Analytik. Wiley-VCH, Weinheim.
47. Akoka S, Barantin L, Trierweiler M (1999) Concentration measurement by proton NMR using the ERETIC method. Anal Chem 71: 2554-2557.
48. Remaud GS, Silvestre V, Akoka S (2005) Traceability in quantitative NMR using an electronic signal as working standard. Accred Qual Assur 10: 415-420.
49. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Vebkataraman G, Austen F, Woodcock J, Sasisekharan R (2008) Contaminated heparin associated with adverse clinical events and activation of the contact system. New Engl J Med 358: 2457-2467.
50. Guerrini M, Beccati D, Shriver Z, Naggi A, Viswanathan K, Bisio A, Capila I, Lansing JC, Gulieri S, Fraser B, Al-Hakim A, Gunay NS, Zhang Z, Robinson L, Buhse L, Nasr M, Woodchock J, Langer R, Venkataraman G, Linhardt RJ, Casu B, Torri G, Sasisekharan R (2008) Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 26: 669-675.
51. 1H-NMR. Collaborative study for quantification and analytical determination of LoD. Pharmeuropa Bio 1: 31-39.
52. Guerrini M, Zhang Z, Shriver Z, Naggi A, Masuko S, Langer R, Casu B, Linhardt RJ, Torri G, Sasisekharan R (2009) Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci 106: 16956-16961.
53. 1H NMR spectroscopy. J Pharm Biomed Anal 49: 1060-1064.
54. Sitkowski J, Bednarek E, Bocian W, Kozerski L (2008) Assessment of oversulfated chondroitin sulfate in low molecular weight and unfractioned heparins diffusion ordered nuclear magnetic resonance spectroscopy method. J Med Chem 51: 7663-76665.
55. Wieglos T, Havel K, Ivanova N, Weinberger R (2009) Determination of impurities in heparin by capillary electrophoresis using high molarity phosphate buffers. J Pharm Biomed Anal 49: 319-326.
56. Volpi N, Maccari F, Linhardt RH (2009) Quantitative capillary electrophoresis determination of oversulfated chondroitin sulfate as a contaminant in heparin preparations. Anal Biochem 388: 140-145.
57. Somsen GW, Tak YH, Toraño JS, Jongen PMJM, de Jong GJ (2009) Determination of oversulfated chondroitin sulfate and dermatan sulfate impurities in heparin by capillary electrophoresis. J Chromatogr A 1216: 4107-4112.
58. Trehy ML, Reepmeyer JC, Kolinski RE, Westenberger BJ, Buhse LF (2009) Analysis of heparin sodium by SAX/HPLC for contaminants and impurities. J Pharm Biomed Anal 49: 670-673.
59. Spencer JA, Kauffman F, Reepmeyer JC, Gryniewicz CM, Ye W, Toler DY, Buhse LF, Westenberger BJ (2009) Screening of heparin API by near infrared reflectance and Raman spectroscopy. J Pharm Science 98: 3540-3547.
60. Norwig J, Beyer T, Brinz D, Holzgrabe U, Diller M, Manns D (2009) Prediction of the oversulphated chondroitin sulphate contamination of unfractionated heparin by ATR-IR spectroscopy. Pharmeur Sci Notes 2009: 17-24.
61. Sun C, Zang H, Lui X, Dong Q, Li L, Wang F, Sui L (2010) Determination of potency of heparin active pharmaceutical ingredient by near infrared reflectance spectroscopy. J Pharm Biomed Anal 51: 1060-1063.
62. Domanig R, Jöbstl W, Gruber S, Freudemann T (2009) One-dimensional cellulose acetate plate electrophoresis-a feasible method for analysis of dermatan sulfate and other glycosaminoglycan impurities in pharmaceutical heparin. J Pharm Biomed Anal 49: 151-155.
63. Zhang Z, Weiwer M, Li B, Kemp MM, Daman TH, Linhardt RJ (2008) Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem 51: 5498-5501.
64. Wang L, Buchanan S, Meyerhoff ME (2008) Detection of high-charge density polyanion contaminants in biomedical heparin preparations using potentiometric polyanion sensors. Anal Chem 80: 9845-9847.
65. Li B, Suwan J, Martin JG, Zhang F, Zhang Z, Hoppensteadt D, Clark M, Farceed J, Linhard RJ (2009) Oversulfated chondroitin sulfate interaction with heparin-binding proteins: new insights into adverse reactions from contaminated heparins. Biochem Pharmacol 78: 292-300.
66. Alban S, Lühn S (2008) Prothrombin time for detection of contaminated heparins. N Engl J Med 359: 2732-2734.
67. 1H NMR, SAX-HPLC, and anticoagulation time approaches. J Pharm Biomed Anal 52: 656-664.
68. Beyer T, Matz M, Brinz D, Rädler O, Wolf B, Norwig J, Baumann K, Alban S, Holzgrabe U (2010) Composition of OSCS-contaminated Heparin Occuring in 2008 in Batches on the German market. Eur J Pharm Sci 40: 297-304.
69. McEwen I, Amini A, Olofsson IM (2010) Identification and purity test of heparin by NMR. A summary of 2 years' experience at the medical products agency. Pharmaeuropa Bio Sci Notes 1: 65-72.
70. 1H-NMR magnetic resonance spectroscopy. J Pharm Sci 78: 101-104.
71. Monograph 0333, Heparin Sodium, European Pharmacopeia 6.8, Council of Europe, Strasbourg, 2010.
72. 13C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin Thromb Hemostas 27: 473-482.
73. 1H-nuclear magnetic resonance spectroscopy. Chem Pharm Bull 38: 2503-2506.
74. Holme KR, Perlin A (1989) Nuclear magnetic resonance spectra of heparin in admixture with dermatan sulfate and other glycosaminoglycans. 2-D spectra of the chondroitin sulfates. Carbohydr Res 186: 301-312.
75. 1H NMR chemical shift of the methyl signal of oversulphated chondroitin sulphate, a contaminant in heparin. J Pharm Biomed Anal 49: 816-819.
76. Sanofi-Aventis presentation (2009) Consequences of OSCS crisis on heparin compliance to USP proposed monograph. At: 3rd workshop on the characterization of heparin products, July 27-28, 2009, Rockville, USA. Available at: http://www. usp. org/pdf/EN/meetings/workshops/heparin2009Viskov2. pdf. Accessed 01 Jun 2010.
77. Monograph 0333, Heparin Sodium, European Pharmacopoeia 6.4, Council of Europe, Strasbourg, 2009.
78. 1H-NMR signals in the spectra of heparin and OSCS by paramagnetic transition metal ions. The use of EDTA to sharpen the signals. J Pharm Biomed Anal 51: 733-735.
79. Casu B, Naggi A, Oreste P, Torri G, Pangrazzj J, Maggi A, Abbadini M, Donati MB (1987) Bleeding associated with heparin contaminants. Lancet 8541: 1088.
80. Guerrini M, Shriver Z, Bisio A, Naggi A, Casu B, Sasisekharan R (2009) The tainted heparin story: an update. Thromb Haemost 102: 907-911.
81. Monograph 0828, Low Molecular Mass Heparins, European Pharmacopoeia 6. 0, Council of Europe, Strasbourg, 2008.
82. Kleemann A, Leuchtenberger W, Hoppe B, Tanner H (1985) Amino Acids. In: Gerhartz W (ed) Ullmann's encyclopedia of industrial chemistry A2. VCH Verlagsgesellschaft Gmbh, Weinheim, pp 57-97.
83. Breuer M, Ditrich K, Habicher T, Hauer B, Keßeler M, Stürmer R, Zelinski T (2004) Industrielle Verfahren zur Herstellung von optische aktiven Zwischenprodukten. Angew Chem 116: 806-843.
84. Blaschek W, Ebel S, Hackenthal E, Holzgrabe U et al (2005) Hagers Handbuch der Drogen und Arzneistoffe. Springer Verlag, Heidelberg.
85. Muller GW, Konnecke WE, Smith AM, Khetani VD (1999) A concise two-step synthesis of thalidomide. Org Process Res Dev 3: 139-140.
86. Körner E, Bertha G, Flooh E, Reinhart B, Wolf R, Lechner H (1986) Sleep-inducing effect of l-tryptophane. Eur Neurol 25: 75-81.
87. Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rösch W, Strauch S (2003) Therapeutic efficacy of l-ornithine-l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 25: 1351-1360.
88. Petritis K, Elfakir C, Dreux M (2002) A comparative study of commercial liquid chromatographic detectors for the analysis of underivatized amino acids. J Chromatogr A 961: 9-21.
89. Hoppe B, Martens J (1984) Aminosäuren-Herstellung und Gewinnung. Chem Unserer Zeit 18: 73-86.
90. Kopec S, Holzgrabe U (2005) Impurity profile of amino acids? Pharmeur Sci Notes 2005: 39-45.
91. Johnsthon LF, Shoolery JN (1962) Determination of unsaturation and average molecular weight of natural fats by nuclear magnetic resonance. Anal Chem 34: 1136-1139.
92. 1H nuclear magnetic resonance spectroscopy. J Am Oil Chem Soc 75: 15-19.
93. Guillén MD, Ruiz A (2003) Rapid simultaneous determination by proton NMR of unsaturation and composition of acyl groups in vegetable oils. Eur J Lipid Sci Technol 105: 688-696.
94. 13C NMR analysis of the triacylglycerol composition of Greek virgin olive oils. Magn Reson Chem 35: 3-7.
95. 1H-nuclear magnetic resonance spectroscopy. J Am Oil Chem Soc 77: 737-748.
96. Diehl BWK (1998) Multinuclear high resolution NMR spectroscopy. In: Hamilton RJ (ed) Lipid analysis of oils and fats. Chapman & Hall, London.
97. Diehl BWK (2001) High resolution NMR spectroscopy. Eur J Lipid Sci Technol 103: 16-20.
98. 1H-NMR spectroscopy. Eur J Lipid Sci Technol 106: 88-96.
99. 1H nuclear magnetic resonance as a fast tool for determining the composition of acyl chains in acylglycerol mixtures. Eur J Lipid Sci Technol 105: 502-507.
100. Wollenberg KF (1990) Quantitative high resolution carbon-13 nuclear magnetic resonance of the olefinic and carbonyl carbons of edible vegetable oils. J Am Oil Chem Soc 67: 487-494.
101. 13C nuclear magnetic resonance of acyl chain carbonyl carbons. Magn Reson Chem 36: 359-362.
102. 13C-NMR of the carbonyl region. Ital J Food Sci 4: 117-123.
103. 13C-NMR spectroscopy. Lipids 20: 778.
104. 13C nuclear magnetic resonance spectroscopy. J Am Oil Chem Soc 77: 749-755.
105. 13C NMR study. Chem Phys Lipids 103: 47-55.
106. Diehl BWK, Linscheid M, Overmöhle M, Heinz M, Riedl I (1997) Membrane lipids of rhodopseudomanas viridis. Biochim Biophys Acta 1347: 151-163.
107. 13C-NMR analysis of the positional distribution of fatty acids in plant glycolipids. Chem Phys Lipids 77: 147-153.
108. Mannina L, Segre A (2002) High resolution nuclear magnetic resonance: from chemical structure to food authenticity. Grasas Aceites 53: 22-33.
109. Mannina L, Sobolev A, Segre A (2003) Olive oil as seen by NMR and chemometrics. Spectroscopy Europe 15: 6-14.
110. Dawe RD, Wright JL (1988) A new quantitative method for the analysis of monoacylglycerol isomers using carbon-13 nuclear magnetic resonance spectroscopy. Lipids 23(4): 355.
111. 31P NMR spectroscopy. J Agr Food Chem 56: 5765-5769.
112. 31P NMR spectroscopy with conventional methods of analysis for the determination of some olive oil constituents. J Agr Food Chem 55: 577-584.
113. 1H-nuclear magnetic resonance study of the minor components in virgin olive oils. J Am Oil Chem Soc 73: 747-758.
114. 13C nuclear magnetic resonance spectroscopy. J Am Oil Chem Soc 70: 965-970.
115. 13C-NMR of virgin olive oil. An overview. Magn Reson Chem 35: 133-145.
116. Miyake Y, Yokomizo K (1998) Determination of cis- and trans-18: 1 fatty acid isomers in hydrogenated vegetable oils by high-resolution carbon nuclear magnetic resonance. J Am Oil Chem Soc 75: 801-805.
117. 13C NMR as a primary method for determining saturates, cis and trans-monounsaturates and polyunsaturates in fats and oils for nutritional labeling purposes. Eur J Lipid Sci Technol 111: 612-622.
118. 1H-NMR determination of 1, 2-and 1, 3-diglycerides in virgin olive oils. Ital J Food Sci 3: 253-262.
119. 31P-NMR of extracted phospholipids. J Lipid Res 29: 679-689.
120. Diehl BWK, Ockels W (1995) Characterization, metabolism and novel biological applications. In: Cevc G, Paltauf F (eds) Proceeding of the 6th international colloquium phospholipids. AOCS, Champaign, pp 29-32.
121. Cabezas DM, Diehl BWK, Tomás MC (2009) Sunflower lecithin: application of a fractionation process with absolute ethanol. J Am Oil Chem Soc 81: 241-244.